CANAGLIFLOZIN PROVIDES GREATER IMPROVEMENT IN RISK FACTORS ASSOCIATED WITH METABOLIC SYNDROME VERSUS GLIMEPIRIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND METABOLIC SYNDROME ON BACKGROUND METFORMIN
AACE ePoster Library. MERTON K. 05/27/16; 131402; 306
KATHERINE MERTON
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Rate & Comment (0)
{{ help_message }}
{{filter}}